AstraZeneca beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand ...

The regulatory actions were based on results from the Phase III MATTERHORN trial (NCT04592913), which showed that a ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) has been accepted and granted ...

(Alliance News) - AstraZeneca PLC on Tuesday reported better-than-expected second quarter revenue, and raised its dividend, boosted by strong sales from its cancer portfolio.

UK pharma major AstraZeneca this morning revealed that its supplemental Biologics License Application (sBLA) for Imfinzi ...

AstraZeneca (LSE:AZN) recently announced plans to invest $50 billion in the U.S. by 2030, including the development of a ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi (durvalumab) to treat adult patients with limited ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that Imfinzi (durvalumab) has been approved in the European Union for the treatment of adult patients with resectable ...

On Friday, AstraZeneca Plc AZN released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable Stage II-IVA ...

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited ...

AIM ImmunoTech shares climbed after the company reported positive data from a Phase 2 study evaluating treatment of metastatic pancreatic cancer patients with stable disease after a combination ...